Browsing by Author "Ay, Pinar"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    COVID-19 Pandemic and the Global Perspective of Turkish Thoracic Society
    (AVES, 2020-01-01) Kokturk, Nurdan; Itil, Bahriye Oya; Altinisik, Goksel; Adiguzel, Nalan; Akgun, Metin; Akyildiz, Levent; Altin, Sedat; Arikan, Huseyin; Ates, Gungor; Ay, Pinar; Aykac, Nilufer; Babayigit, Cenk; Bostan, Pinar; Cinel, Guzin; Calisir, Haluk Celaleddin; Celik, Pinar; Cetinkaya, Pelin Duru; Dagli, Elif; Demir, Ahmet Ugur; Demir, Canan; Dikensoy, Oner; Edis, Ebru Cakir; Elbek, Osman; Erdinc, Munevver; Ergan, Begum; Eyuboglu, A. Fusun Oner; Gemicioglu, Bilun; Goksel, Tuncay; Gulhan, Erkmen; Gultekin, Okkes; Gurkan, Canan Gunduz; Gurgun, Alev; Havlucu, Yavuz; Basoglu, Ozen K.; Karakurt, Sait; Karkurt, Zuhal; Kilinc, Oguz; Kocabas, Ali; Kul, Seval; Musellim, Benan; Nayci, Sibel; Ozkan, Metin; Pinarer, Ozgun; Salturk, Cuneyt; Sandal, Abdulsamet; Sayiner, Abdullah; Sen, Elif; Simsek, Gokcen Omeroglu; Karadag, Bulent Taner; Akyil, Fatma Tokgoz; Toreyin, Zehra Nur; Ucan, Eyup Sabri; Kucuk, Filiz Cagla Uyanusta; Varol, Ayhan; Yasin, Yesim; Yildiz, Tekin; Yorgancioglu, A. Arzu; Bayram, Hasan; Foll, Turkish Thoracic Soc C. O. V. I. D.-19
    It has been more than 3 months now since the first case of COVID-19 was reported in Turkey. Globally, the number of confirmed cases and deaths reached 9,653,048 and 491,128 respectively, as reported by 216 countries by June 27, 2020. Turkey had 1,396 new cases, 194,511 total cases, and 5,065 deaths by the same date. From the first case until today, the Turkish Thoracic Society (TTS) has been very proactive in educating doctors, increasing public awareness, undertaking academic studies, and assisting with public health policies. In the present report, social, academic, and management perspectives of the pandemic are presented under appropriate subtitles. During this critical public health crisis, TTS has once again demonstrated its readiness and constructive stance by supporting public health, healthcare workers, and the environment. This review summarizes the perspective of TTS on each aspect of the COVID-19 pandemic and casts light on its contributions.
  • Thumbnail Image
    Item
    Pharmacokinetic characterization of favipiravir in patients with COVID-19
    (WILEY, 2022-01-01) Gulhan, Rezzan; Eryuksel, Emel; Oglu, Medine Gulcebi Idriz; Culpan, Yekta; Toplu, Aylin; Kocakaya, Derya; Tigen, Elif; Sengel, Buket Erturk; Sili, Uluhan; Yildizeli, Sehnaz Olgun; Balcan, Mehmet Baran; Elci, Abdullah; Bulut, Cenk; Karaalp, Atila; Yananli, Hasan Raci; Guner, Abdullah Emre; Hatipoglu, Mustafa; Karakurt, Sait; Korten, Volkan; Ratnaraj, Neville; Patsalos, Philip; Ay, Pinar; Onat, Filiz
    This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID-19 with a positive RT-PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in-hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID-19. The median favipiravir trough concentration (C0-trough) on Day 2 was 21.26 (interquartile range {[}IQR], 8.37-30.78) mu g/mL, whereas it decreased significantly to 1.61 (IQR, 0.00-6.41) mu g/mL on Day 4, the area under the concentration-time curve decreased by 68.5\%. Day 2 C0-trough of female patients was higher than male patients. Our findings indicate that favipiravir concentrations show significant variability during the treatment of COVID-19 and therapeutic drug monitoring may be necessary to maintain targeted concentrations.